Expert Illustrations and Commentaries: Translating Advances in XLH and TIO Into Practical Strategies for Management

Released On
January 20, 2021

Expires On
January 20, 2022

Media Type
Internet

Completion Time
60 minutes

Specialty
Endocrinology, Genetics, Pain Management, Pediatrics, Primary Care

Topic(s)
Metabolic Disorders, Pain, Pediatrics, Surgery

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Ultragenyx Pharmaceutical Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed primarily toward endocrinologists, rheumatologists, nephrologists, pediatricians, primary care providers, geneticists, nurse practitioners, and physician assistants. The secondary target audience includes pharmacists, managed care professionals, neurologists, orthopedists, radiologists, fellows and other health care professionals involved in the care of patients with XLH or TIO.

Activity Overview

As chronic diseases, X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) have a debilitating impact on the quality of life of affected patients. In XLH, significant complications result from unresolved symptoms in childhood, as well as from disease progression. In TIO, difficulties locating or resecting the causative tumor can result in lifelong morbidity. Unfortunately, knowledge of these conditions is also limited, and many patients experience delayed diagnoses and ineffective treatment.

This activity provides clinicians with a deeper understanding of XLH and TIO in terms of the pathophysiology and clinical presentation so they can better manage patients. In this activity, the faculty describe available novel therapies and their unique mechanisms in order to better select treatments for patients. They also explain the mechanism of action of novel therapies for XLH and TIO. In addition, a white board animation helps to illustrate this for participants.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the pathophysiological basis for the development of symptoms in patients with XLH or TIO
  • Identify clinical presentations of XLH and TIO that warrant further investigation and diagnostic testing
  • Discuss the mechanisms of action for novel and emerging therapies in the management of patients with XLH or TIO
  • Apply traditional and emerging therapeutic approaches toward the development of management plans for patients with XLH or TIO

Faculty

FACULTY_NAME

Thomas O. Carpenter, MD

Professor of Pediatrics (Endocrinology)
Professor of Orthopedics and Rehabilitation
Yale University School of Medicine
New Haven, CT

FACULTY_NAME

Peter Tebben, MD

Mayo Clinic
Departments of Internal Medicine and Pediatrics
Division of Endocrinology
Rochester, MN

Accreditation Statement

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Disclosures of Conflicts of Interest

In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Thomas O. Carpenter, MD

  • Grant Research Support: Ultragenyx
  • Consultant: Ultragenyx, Inozyme Pharma, Regeneron Pharmaceuticals, Kyowa Hakko Kirin Pharma

Peter Tebben, MD

  • Grant Research Support: Ultragenyx
  • Other: Ultragenyx: CME

The staff of Physicians’ Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.
Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.